-
公开(公告)号：US20240252432A1
公开(公告)日：2024-08-01
申请号：US18577176
申请日：2022-07-08
发明人： Vidya JOSHI , James ARCHBELL , Kellisa LACHACZ , Charina LAMPA , Lauren MELLO , Gertrude GUTIERREZ , David LECHUGA-BALLESTEROS , Penny TAN , Michael RIEBE
IPC分类号： A61K9/00 , A61K9/16 , A61K31/167 , A61K31/4015 , A61K31/44 , A61K31/58
CPC分类号： A61K9/008 , A61K9/1617 , A61K31/167 , A61K31/4015 , A61K31/44 , A61K31/58
摘要： Compositions, methods, and systems are provided for pulmonary delivery of active agents via a metered dose inhaler. In some embodiments, the compositions comprise an HFO-1234ze(E) suspension medium, active agent particles, and suspending particles. The active agent particles may comprise one, two, three or four active agent(s) selected from a long-acting muscarinic antagonist (LAMA), a long-acting β2-agonists (LABA), a short-acting beta-agonists (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent.
-
公开(公告)号：US20180333468A1
公开(公告)日：2018-11-22
申请号：US15888519
申请日：2018-02-05
发明人： Mark FINEMAN , Leigh MACCONELL , Kristin TAYLOR
摘要： Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
-
公开(公告)号：US20170114114A1
公开(公告)日：2017-04-27
申请号：US15398627
申请日：2017-01-04
发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Swetha Neravetla , Chengzao Sun , Manoj P. Samant , Odile E. Levy , Abhinandini Sharma , Lala Mamedova , Christopher Soares
IPC分类号： C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , A61K47/643 , C07K14/57563 , C07K14/605 , C07K2319/00 , C07K2319/21 , C07K2319/70
摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
-
公开(公告)号：US09593154B2
公开(公告)日：2017-03-14
申请号：US13852899
申请日：2013-03-28
发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Swetha Neravetla , Chengzao Sun , Manoj P. Samant , Odile E. Levy , Abhinandini Sharma , Lala Mamedova , Christopher J. Soares
IPC分类号： C07K14/605 , A61K47/48 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , A61K47/643 , C07K14/57563 , C07K14/605 , C07K2319/00 , C07K2319/21 , C07K2319/70
摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
摘要翻译： 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括口服给药。 所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。 还提供药物组合物和治疗疾病和障碍的方法，包括肥胖和超重，糖尿病，血脂异常，高脂血症，阿尔茨海默病，脂肪肝疾病，短肠综合征，帕金森病，心血管疾病等中枢神经系统疾病 。
-
公开(公告)号：US20160346357A1
公开(公告)日：2016-12-01
申请号：US15234021
申请日：2016-08-11
发明人： Mary L. HOUCHIN , Robin H. LEE , Hong QI , Greg OEHRTMAN , Robert N. JENNINGS , Scott H. COLEMAN
CPC分类号： A61K38/2278 , A61K9/0019 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1647 , A61K9/5153 , A61K31/00 , A61K31/60 , A61K31/65 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/14 , A61K47/44 , A61K2300/00
摘要： The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.
-
6.发明申请PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME 审中-公开胰蛋白多糖家族动物，聚合物及其包含的方法公开(公告)号：US20150231204A1
公开(公告)日：2015-08-20
申请号：US14539540
申请日：2014-11-12
发明人： Odile Esther LEVY , Carolyn M. Jodka , Soumitra S. Ghosh , David G. Parkes , Richard A. Pittner , Lawrence J. D'Souza , John S. Ahn , Kathryn S. Prickett , Jonathan David Roth , Sean H. Adams
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/00 , C07K14/475 , C07K14/575
摘要： The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
摘要翻译： 本发明提供新型胰腺多肽家族（“PPF”）多肽及其使用方法。
-
7.发明授权Method of lowering cholesterol and triglycerides by administering exendins 有权通过施用毒蜥外泌肽降低胆固醇和甘油三酸酯的方法公开(公告)号：US09034819B2
公开(公告)日：2015-05-19
申请号：US13774931
申请日：2013-02-22
发明人： Mark Fineman , Leigh MacConell , Kristin Taylor
CPC分类号： A61K38/179 , A61K9/5031 , A61K38/2278 , A61K38/26 , A61K47/34
摘要： Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.
摘要翻译： 本文提供含有以持续时间段以治疗血浆浓度水平施用以降低总胆固醇水平的毒蜥吐宁，毒蜥外泌肽激动剂或毒蜥外泌肽类似物激动剂的药物制剂; 降低低密度脂蛋白胆固醇水平; 降低甘油三酯水平; 治疗血脂异常 治疗和减缓动脉粥样硬化的进展; 并治疗，预防和减少患者心脏病发作和中风的风险。 在本发明的药物制剂和方法中，毒蜥外泌肽可以是毒蜥外泌肽-4，毒蜥外泌肽-4激动剂或毒蜥外泌肽-4类似物激动剂。 药物制剂可以是可以每周一次施用的基于聚合物的药物制剂。 示例性的药物制剂包含5％（w / w）的艾塞那肽，约2％（w / w）的蔗糖和约93％（w / w）的聚（丙交酯 - 共 - 乙交酯）聚合物，其中聚 （丙交酯 - 共 - 乙交酯）聚合物是包封艾塞那肽的微球的形式。
-
公开(公告)号：US20140249299A1
公开(公告)日：2014-09-04
申请号：US14195262
申请日：2014-03-03
发明人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
IPC分类号： C07K14/575 , C07K14/605
CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的包括1型，2型和妊娠糖尿病的糖尿病。
-
公开(公告)号：US20140221282A1
公开(公告)日：2014-08-07
申请号：US14119581
申请日：2012-05-24
发明人： Chengzao Sun , Behrouz Bruce Forood
CPC分类号： A61K38/26 , A61K38/00 , A61K38/22 , A61K47/60 , C07K14/575
摘要： There are provided compounds having two peptide hormones bound to a central water-soluble polymeric spacer and methods of use thereof.
摘要翻译： 提供了具有与中心水溶性聚合间隔物结合的两种肽激素的化合物及其使用方法。
-
公开(公告)号：US20140200183A1
公开(公告)日：2014-07-17
申请号：US14221634
申请日：2014-03-21
发明人： David R. HATHAWAY , Alain D. BARON
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , A61K31/7004 , A61K33/00 , A61K38/2278
摘要： Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
摘要翻译： 本发明的组合物，包括与胰高血糖素样肽-1的受体结合的化合物，肠降血糖素，胰高血糖素样肽-1（GLP-1），毒蜥外泌肽或激动剂，类似物（优选激动剂 类似物），任何前述化合物的衍生物或变体，用于预防和治疗与心脏缺血，心脏缺血灌注和/或充血性心力衰竭相关的心律失常。 本发明涉及这种治疗的方法和组合物。
-
-
-
-
-
-
-
-
-
搜索结果
53 条记录 (耗时 0.054 秒)
